文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

多支冠状动脉疾病患者冠状动脉旁路移植术前给予依洛尤单抗(EVOCABG):随机对照临床试验研究方案

Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2022-05-23

EVOCABG 是一项前瞻性、随机、开放、对照、多中心、优效性 III 期临床试验,拟纳入 100 例无初始心肌酶升高的多支冠状动脉疾病患者。受试者随机分为试验组(CABG 术前 72 小时内给予依洛尤单抗 140mg 一次)和对照组(不给药)。主要结局是 CABG 术后 3 天内血清心肌标志物肌钙蛋白-I 峰值水平较基线的变化。

要点

  • EVOCABG 拟纳入 100 例多支冠状动脉疾病且无初始心肌酶升高的患者。
  • 试验组在 CABG 术前 72 小时内给予依洛尤单抗 140mg 一次,对照组不给药。
  • 主要结局为 CABG 术后 3 天内肌钙蛋白-I 峰值水平较基线的变化。

核心结论

  • 该试验是首个前瞻性随机对照试验,旨在证明依洛尤单抗可减轻 CABG 患者的缺血再灌注损伤。
  • 该试验将为 CABG 术前使用依洛尤单抗减轻或预防术中缺血再灌注相关心肌损伤提供首个高质量证据。

研究设计与样本

  • EVOCABG 为前瞻性、随机、开放、对照、多中心、优效性 III 期临床试验。
  • 拟纳入多支冠状动脉疾病且无初始心肌酶升高的患者 n=100。
  • 受试者随机分为试验组(CABG 术前 72 小时内给予依洛尤单抗 140mg 一次)和对照组(不给药)。

关键数值与推荐

  • 主要结局为 CABG 术后 3 天内血清心肌标志物肌钙蛋白-I 峰值水平较基线的变化。
  • 次要结局包括术后临床事件:死亡、心肌梗死、心力衰竭、卒中和心房颤动。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in surgical and postoperative care, myocardial injury or infarction (MI) is still a common complication in patients undergoing coronary artery bypass surgery (CABG). Several studies that aimed to reduce postoperative myocardial injury, including those investigating statin loading, have been conducted but did not indicate any clear benefits. Evolocumab, a PCSK9 inhibitor, has been reported to lower lipids and prevent ischemic events in various medical conditions. However, the effect of evolocumab in cardiovascular surgery has not been evaluated. The objective of this trial is to evaluate the cardioprotective effects of evolocumab in elective CABG patients with multivessel coronary artery disease. METHODS: EVOCABG is a prospective, randomized, open, controlled, multicenter, superiority, phase III clinical trial. Patients with multivessel coronary artery disease without initial cardiac enzyme elevation will be recruited (n=100). Participants will be randomly allocated into two groups: a test group (evolocumab (140mg) administration once within 72 h before CABG) and a control group (no administration). The primary outcome is the change in peak levels of serum cardiac marker (troponin-I) within 3 days of CABG surgery compared to the baseline. Secondary outcomes include post-operative clinical events including death, myocardial infarction, heart failure, stroke, and atrial fibrillation. DISCUSSION: This trial is the first prospective randomized controlled trial to demonstrate the efficacy of evolocumab in reducing ischemic-reperfusion injury in patients undergoing CABG. This trial will provide the first high-quality evidence for preoperative use of evolocumab in mitigating or preventing ischemic-reperfusion-related myocardial injury during the surgery. TRIAL REGISTRATION: Clinical Research Information Service (CRIS) of the Republic of Korea KCT0005577 . Registered on 4 November 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Na HR, Kwon OS, Kang JK, et al. Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial. Trials. 2022. PMID: 35606883. doi:10.1186/s13063-022-06398-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。